Loading...
XTAI4737
Market cap121mUSD
Dec 24, Last price  
65.00TWD
1D
-0.15%
1Q
-6.74%
Jan 2017
16.28%
IPO
-35.66%
Name

Bionime Corp

Chart & Performance

D1W1MN
XTAI:4737 chart
P/E
638.74
P/S
2.26
EPS
0.10
Div Yield, %
3.22%
Shrs. gr., 5y
1.06%
Rev. gr., 5y
-2.64%
Revenues
1.76b
-20.58%
937,752,0001,211,743,0001,476,543,0001,435,022,0001,560,897,0001,524,669,0001,609,718,0001,740,309,0001,820,267,0002,007,222,0002,172,923,0001,668,586,0001,849,924,0002,210,589,0001,755,567,000
Net income
6m
-93.18%
135,237,000136,050,000179,111,00034,147,00089,929,00054,309,00098,793,000178,790,000149,608,000128,032,000106,258,00062,434,00087,413,00091,025,0006,209,000
CFO
203m
+42.98%
207,558,00013,661,000216,930,00023,575,000128,981,000359,843,000200,365,000457,836,00029,599,000121,898,000405,556,000217,556,000269,722,000142,292,000203,443,000
Dividend
Jul 29, 20241.99997 TWD/sh
Earnings
Jun 27, 2025

Profile

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.
URL
https://www.bionime.com/
IPO date
Aug 26, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,755,567
-20.58%
2,210,589
19.50%
1,849,924
10.87%
Cost of revenue
1,805,420
2,049,585
1,795,192
Unusual Expense (Income)
NOPBT
(49,853)
161,004
54,732
NOPBT Margin
7.28%
2.96%
Operating Taxes
(38,406)
(5,337)
(14,740)
Tax Rate
NOPAT
(11,447)
166,341
69,472
Net income
6,209
-93.18%
91,025
4.13%
87,413
40.01%
Dividends
(127,685)
(121,204)
(124,284)
Dividend yield
2.79%
2.56%
2.70%
Proceeds from repurchase of equity
10,464
9,319
30,562
BB yield
-0.23%
-0.20%
-0.66%
Debt
Debt current
1,119,851
779,545
874,575
Long-term debt
1,717,580
1,500,182
1,162,516
Deferred revenue
Other long-term liabilities
558
630
950
Net debt
2,389,794
2,029,138
1,747,906
Cash flow
Cash from operating activities
203,443
142,292
269,722
CAPEX
(293,081)
(312,921)
(284,569)
Cash from investing activities
(435,261)
(312,256)
(288,070)
Cash from financing activities
420,405
113,635
(69,297)
FCF
(94,864)
53,625
36,119
Balance
Cash
449,213
277,877
312,910
Long term investments
(1,576)
(27,288)
(23,725)
Excess cash
359,859
140,060
196,689
Stockholders' equity
761,443
1,217,165
1,128,482
Invested Capital
4,451,097
4,204,904
3,904,284
ROIC
4.10%
1.81%
ROCE
3.71%
1.33%
EV
Common stock shares outstanding
61,252
61,424
60,827
Price
74.80
-3.11%
77.20
1.85%
75.80
11.63%
Market cap
4,581,650
-3.38%
4,741,933
2.85%
4,610,687
12.47%
EV
6,978,614
6,779,182
6,365,321
EBITDA
113,569
314,236
209,389
EV/EBITDA
61.45
21.57
30.40
Interest
48,234
30,648
19,051
Interest/NOPBT
19.04%
34.81%